Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis

This publication has 18 references indexed in Scilit:

• Sequence-dependent enhancement of paclitaxel toxicity in non–small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin
  The Journal of Thoracic and Cardiovascular Surgery, 1999
• Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells
  Oncogene, 1998
• Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung
  The Annals of Thoracic Surgery, 1998
• The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
  Cancer Chemotherapy and Pharmacology, 1998
• Depletion of p185 erbB2 , Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
  Cancer Chemotherapy and Pharmacology, 1997
• Prediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissue
  British Journal of Cancer, 1997
• Enhanced Chemoresistance by Elevation of p185neu Levels in HER-2/neu-Transfected Human Lung Cancer Cells
  JNCI Journal of the National Cancer Institute, 1995
• Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line
  British Journal of Cancer, 1995
• Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent
  Cancer Chemotherapy and Pharmacology, 1995
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987